Journal
MBIO
Volume -, Issue -, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/mbio.01295-23
Keywords
respiratory viruses; mucosal immunity; antiviral agents; inhalation; vaccines; dry powder formulation; pulmonary administration; dry powder inhaler; IgA; aerosols; spray drying; SARS-CoV-2
Categories
Ask authors/readers for more resources
The pulmonary route of administration plays an important role in the treatment of respiratory virus infections, as it can induce a broader immune response and improve drug bioavailability.
Many of the current pandemic threats are caused by viruses that infect the respiratory tract. Remarkably though, the majority of vaccines and antiviral drugs are administered via alternative routes. In this perspective, we argue that the pulmonary route of administration deserves more attention in the search for novel therapeutic strategies against respiratory virus infections. Firstly, vaccines administered at the viral portal of entry can induce a broader immune response, employing the mucosal arm of the immune system; secondly, direct administration of antiviral drugs at the target site leads to superior bioavailability, enabling lower dosing and reducing the chance of side effects. We further elaborate on why the pulmonary route may induce a superior effect compared to the intranasal route of administration and provide reasons why dry powder formulations for inhalation have significant advantages over standard liquid formulations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available